These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11497346)

  • 1. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.
    Iversen PL
    Curr Opin Mol Ther; 2001 Jun; 3(3):235-8. PubMed ID: 11497346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A; Iversen PL
    Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.
    Deere J; Iversen P; Geller BL
    Antimicrob Agents Chemother; 2005 Jan; 49(1):249-55. PubMed ID: 15616302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on antisense therapy for the prevention of restenosis.
    Kipshidze N; Moses J; Shankar LR; Leon M
    Curr Opin Mol Ther; 2001 Jun; 3(3):265-77. PubMed ID: 11497351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.
    Nelson MH; Stein DA; Kroeker AD; Hatlevig SA; Iversen PL; Moulton HM
    Bioconjug Chem; 2005; 16(4):959-66. PubMed ID: 16029037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin.
    Pannier AK; Arora V; Iversen PL; Brand RM
    Int J Pharm; 2004 May; 275(1-2):217-26. PubMed ID: 15081152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.
    Tilley LD; Mellbye BL; Puckett SE; Iversen PL; Geller BL
    J Antimicrob Chemother; 2007 Jan; 59(1):66-73. PubMed ID: 17079242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.
    Arora V; Devi GR; Iversen PL
    Curr Pharm Biotechnol; 2004 Oct; 5(5):431-9. PubMed ID: 15544491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
    Orr RM
    Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers.
    Ghosh C; Iversen PL
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):263-74. PubMed ID: 10984120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense drug discovery and development.
    Yamamoto T; Nakatani M; Narukawa K; Obika S
    Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morpholino antisense oligomers: the case for an RNase H-independent structural type.
    Summerton J
    Biochim Biophys Acta; 1999 Dec; 1489(1):141-58. PubMed ID: 10807004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro transcription and translation inhibition via DNA functionalized gold nanoparticles.
    Conde J; de la Fuente JM; Baptista PV
    Nanotechnology; 2010 Dec; 21(50):505101. PubMed ID: 21098932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
    Mitrpant C; Fletcher S; Iversen PL; Wilton SD
    J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
    Iversen PL; Arora V; Acker AJ; Mason DH; Devi GR
    Clin Cancer Res; 2003 Jul; 9(7):2510-9. PubMed ID: 12855625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
    Agrawal S
    Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulation of zebrafish embryogenesis by phosphorodiamidate morpholino oligomers indicates minimal non-specific teratogenesis.
    Iversen PL; Newbry S
    Curr Opin Mol Ther; 2005 Apr; 7(2):104-8. PubMed ID: 15844616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.